XA FACTOR INHIBITOR RIVAROXABAN IN ATRIAL FIBRILLATION


I.V.Zotova, D.A.Zateyshchikov

The article presents data concerning rivaroxaban, a first factor Xa inhibitor that was approved for clinical use. Pharmacodynamics and pharmacokinetics of the drug, drug interactions, and clinical aspects of the application are discussed. The results of large randomized phase III ROCKET-AF study which evaluated the effectiveness of rivaroxaban compared with warfarin are analyzed. Based on the results of this study, rivaroxaban has been registered in Russia as an alternative to warfarin for the prevention of thromboembolic complications in patients with atrial fibrillation.

Similar Articles


Бионика Медиа